Real-time Stock quotes, portfolio, LIVE TV and more.
Novartis reaches agreement to develop and commercialize glaucoma treatment with novel mechanism of action
Tags: Novartis , agreement , commercialize glaucoma treatment , novel mechanism , action, Japan, Rho Kinase inhibitor , Senju Pharmaceutical , glaucoma
May 23 2013, 10:43
- in MARKET OUTLOOK
May 23 2013, 09:33
- in Technicals